BioCorRx (BICX) Payables (2010 - 2026)

BioCorRx has disclosed Payables across 17 years of filings, most recently posting $7.8 million for Q1 2026.

• Payables for Q1 2026 came in at $7.8 million, down 36.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.8 million (down 36.66% YoY), and the FY2025 annual result was $7.6 million, up 9.65% from the prior year.
• Payables came in at $7.8 million for Q1 2026 at BioCorRx, up from $7.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $13.4 million in Q2 2025 to a low of $1.6 million in Q3 2025.
• The 5-year median for Payables is $5.1 million (2024), against an average of $6.0 million.
• Peak annual rise in Payables reached 143.81% in 2025, while the deepest fall reached 77.75% in 2025.
• BioCorRx's Payables stood at $4.2 million in 2022, then increased by 24.98% to $5.3 million in 2023, then soared by 31.62% to $6.9 million in 2024, then advanced by 9.65% to $7.6 million in 2025, then climbed by 3.15% to $7.8 million in 2026.
• The last three Payables figures came in at $7.8 million (Q1 2026), $7.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.